ZA201104349B - Pharmaceutical preparation comprising supernatant of blood mononuclear cell culture - Google Patents
Pharmaceutical preparation comprising supernatant of blood mononuclear cell cultureInfo
- Publication number
- ZA201104349B ZA201104349B ZA2011/04349A ZA201104349A ZA201104349B ZA 201104349 B ZA201104349 B ZA 201104349B ZA 2011/04349 A ZA2011/04349 A ZA 2011/04349A ZA 201104349 A ZA201104349 A ZA 201104349A ZA 201104349 B ZA201104349 B ZA 201104349B
- Authority
- ZA
- South Africa
- Prior art keywords
- supernatant
- cell culture
- pharmaceutical preparation
- blood mononuclear
- mononuclear cell
- Prior art date
Links
- 239000008280 blood Substances 0.000 title 1
- 210000004369 blood Anatomy 0.000 title 1
- 238000004113 cell culture Methods 0.000 title 1
- 210000005087 mononuclear cell Anatomy 0.000 title 1
- 239000000825 pharmaceutical preparation Substances 0.000 title 1
- 239000006228 supernatant Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/16—Blood plasma; Blood serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
- A61K39/4621—Cellular immunotherapy characterized by the effect or the function of the cells immunosuppressive or immunotolerising
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/46433—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Cell Biology (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Developmental Biology & Embryology (AREA)
- Virology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Dermatology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Surgery (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP08450198A EP2198873A1 (en) | 2008-12-18 | 2008-12-18 | Pharmaceutical preparation comprising supernatant of blood mononuclear cell culture |
PCT/EP2009/067534 WO2010079086A1 (en) | 2008-12-18 | 2009-12-18 | Pharmaceutical preparation comprising supernatant of blood mononuclear cell culture |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA201104349B true ZA201104349B (en) | 2012-02-29 |
Family
ID=40478351
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA2011/04349A ZA201104349B (en) | 2008-12-18 | 2011-06-10 | Pharmaceutical preparation comprising supernatant of blood mononuclear cell culture |
Country Status (13)
Country | Link |
---|---|
US (1) | US11235003B2 (en) |
EP (2) | EP2198873A1 (en) |
JP (1) | JP5869343B2 (en) |
CN (1) | CN102256608B (en) |
AU (1) | AU2009336668B2 (en) |
BR (1) | BRPI0922174A2 (en) |
CA (1) | CA2746862C (en) |
ES (1) | ES2429518T3 (en) |
NZ (1) | NZ593364A (en) |
PL (1) | PL2379085T3 (en) |
RU (1) | RU2533253C2 (en) |
WO (1) | WO2010079086A1 (en) |
ZA (1) | ZA201104349B (en) |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX2011009277A (en) * | 2009-03-05 | 2011-12-16 | Macrocure Ltd | Activated leukocyte composition. |
WO2015046627A1 (en) * | 2013-09-30 | 2015-04-02 | 国立大学法人九州大学 | Wound healing promoter |
KR102215667B1 (en) * | 2016-05-30 | 2021-02-16 | 주식회사 젬백스앤카엘 | Composition for skin regeneration and anti-aging comprising peripheral blood-derived mononuclear cells and platelet-rich plasma, and skin regeneration method using the same |
TWI732787B (en) * | 2016-10-04 | 2021-07-11 | 訊聯生物科技股份有限公司 | Preparation method of multi-peptide composition stimulated by temperature regulation |
EP3305306A1 (en) * | 2016-10-04 | 2018-04-11 | Dr. Sarah Prinzessin von Isenburg | Compositions comprising adjustable concentrations of growth factors derived from blood serum and clot hypoxia-conditioned medium and methods of their production |
CN106265738A (en) * | 2016-11-11 | 2017-01-04 | 上海鸣大生物科技有限公司 | A kind of external used medicine for treating pathogenic infection dermatoses and its preparation method and application |
CN106344612A (en) * | 2016-11-11 | 2017-01-25 | 上海鸣大生物科技有限公司 | External medicine for treating autoimmune dermatosis and preparation method and application thereof |
CN106491645A (en) * | 2016-11-11 | 2017-03-15 | 上海鸣大生物科技有限公司 | One kind is used for treating physical property dermatosiss and the dermopathic external used medicine of animality and its preparation method and application |
CN106344613A (en) * | 2016-11-11 | 2017-01-25 | 上海鸣大生物科技有限公司 | Application of NK cell stock solution in preparation of medicine for treating skin diseases |
CN106265737A (en) * | 2016-11-11 | 2017-01-04 | 上海鸣大生物科技有限公司 | A kind of external used medicine for treating skin appendages and itching skin disease and its preparation method and application |
CN106389467A (en) * | 2016-11-11 | 2017-02-15 | 上海鸣大生物科技有限公司 | External use medicine for treating dermatitis and eczema type skin diseases, and preparation method and application thereof |
KR102311057B1 (en) * | 2017-12-14 | 2021-10-08 | (주)녹십자웰빙 | Cosmetic composition and pharmaceutical composition for improving atopic dermatis, alopetic, wound, or skin wrinkle |
KR102014467B1 (en) * | 2017-12-14 | 2019-08-26 | (주)녹십자웰빙 | Cosmetic composition and pharmaceutical composition for improving atopic dermatis, alopetic, wound, or skin wrinkle |
CN108042567A (en) * | 2017-12-15 | 2018-05-18 | 广州金塞迩中西医结合医院有限公司 | For the life assemblage preparation of repair of cartilage and its application |
EP3502692A1 (en) * | 2017-12-20 | 2019-06-26 | Aposcience AG | Potency assay for secretomes |
KR102216710B1 (en) * | 2019-03-27 | 2021-02-17 | 신지섭 | NK cell culture medium, NK cell culture method using the above-mentioned additive composition, and cosmetic composition for skin trouble improvement obtained by the above culture method |
EP3962493A2 (en) | 2019-05-03 | 2022-03-09 | Flagship Pioneering Innovations V, Inc. | Methods of modulating immune activity/level of irf or sting or of treating cancer, comprising the administration of a sting modulator and/or purinergic receptor modulator or postcellular signaling factor |
EP3842064A1 (en) | 2019-12-23 | 2021-06-30 | Aposcience AG | Composition for treating or preventing an allergy or allergic reaction |
CN111334472A (en) * | 2020-03-27 | 2020-06-26 | 郑州鲲鹏健康科技有限公司 | PBMC (peripheral vascular endothelial cell) in-vitro 3D collagen hydrogel culture medium and preparation method thereof |
CN111773249A (en) * | 2020-07-31 | 2020-10-16 | 上海鸣大生物科技有限公司 | Composition and preparation method thereof |
WO2022140457A1 (en) | 2020-12-21 | 2022-06-30 | Flagship Pioneering Innovations V, Inc. | Use of cell turnover factors for increasing tissue regeneration |
EP4074320A1 (en) | 2021-04-13 | 2022-10-19 | Aposcience AG | Treatment of skin scars |
EP4197547A1 (en) * | 2021-12-20 | 2023-06-21 | Aposcience AG | Composition for treating or preventing vasculitis and diseases associated with vasculitis |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2320491A1 (en) * | 1998-03-30 | 1999-10-07 | I.D.M. Immuno-Designed Molecules | Stimulated monocyte derived cells, their preparation and uses |
US6372494B1 (en) * | 1999-05-14 | 2002-04-16 | Advanced Tissue Sciences, Inc. | Methods of making conditioned cell culture medium compositions |
AU2003230321B8 (en) * | 2002-05-09 | 2009-07-30 | Medigenes | A pharmaceutical composition for treatment of wounds containing blood plasma or serum |
US20070110737A1 (en) * | 2003-12-29 | 2007-05-17 | Allan Mishra | Compositions and method for decreasing the appearance of skin wrinkles |
WO2005085424A2 (en) * | 2004-03-09 | 2005-09-15 | Absorber Ab | Endothelial progenitor cells and methods of use thereof |
US20060004189A1 (en) * | 2004-07-02 | 2006-01-05 | James Gandy | Compositions for treating wounds and processes for their preparation |
CA2613193A1 (en) * | 2005-06-24 | 2007-01-04 | Ramtin Agah | Thrombospondin-1 derived peptides and treatment methods |
RU2295963C1 (en) * | 2005-10-18 | 2007-03-27 | Закрытое акционерное общество Научно-производственное предприятие "Тринита" | Method for producing immunostimulator |
EP2019590A4 (en) * | 2006-05-03 | 2011-08-03 | Therakos Inc | Methods for treating diseases involving stress-related diseases and conditions |
BRPI0919804A8 (en) * | 2008-10-05 | 2016-10-11 | Friedlander Hymie | METHODS AND COMPOSITION FOR THE TREATMENT OF DERMATOLOGICAL PROBLEMS AND/OR HAIR CONDITIONS |
EP2201954A1 (en) * | 2008-12-18 | 2010-06-30 | Aposcience AG | Pharmaceutical preparation |
-
2008
- 2008-12-18 EP EP08450198A patent/EP2198873A1/en not_active Withdrawn
-
2009
- 2009-12-18 ES ES09795769T patent/ES2429518T3/en active Active
- 2009-12-18 PL PL09795769T patent/PL2379085T3/en unknown
- 2009-12-18 JP JP2011541477A patent/JP5869343B2/en active Active
- 2009-12-18 BR BRPI0922174A patent/BRPI0922174A2/en not_active Application Discontinuation
- 2009-12-18 RU RU2011129676/15A patent/RU2533253C2/en active
- 2009-12-18 AU AU2009336668A patent/AU2009336668B2/en active Active
- 2009-12-18 WO PCT/EP2009/067534 patent/WO2010079086A1/en active Application Filing
- 2009-12-18 EP EP09795769.0A patent/EP2379085B1/en active Active
- 2009-12-18 US US13/140,097 patent/US11235003B2/en active Active
- 2009-12-18 CN CN2009801513863A patent/CN102256608B/en active Active
- 2009-12-18 CA CA2746862A patent/CA2746862C/en active Active
- 2009-12-18 NZ NZ593364A patent/NZ593364A/en unknown
-
2011
- 2011-06-10 ZA ZA2011/04349A patent/ZA201104349B/en unknown
Also Published As
Publication number | Publication date |
---|---|
CA2746862C (en) | 2017-08-29 |
NZ593364A (en) | 2012-11-30 |
CA2746862A1 (en) | 2010-07-15 |
BRPI0922174A2 (en) | 2015-12-29 |
US11235003B2 (en) | 2022-02-01 |
EP2198873A1 (en) | 2010-06-23 |
WO2010079086A1 (en) | 2010-07-15 |
CN102256608B (en) | 2013-12-04 |
AU2009336668B2 (en) | 2014-05-08 |
RU2011129676A (en) | 2013-01-27 |
EP2379085A1 (en) | 2011-10-26 |
EP2379085B1 (en) | 2013-07-10 |
RU2533253C2 (en) | 2014-11-20 |
ES2429518T3 (en) | 2013-11-15 |
JP5869343B2 (en) | 2016-02-24 |
PL2379085T3 (en) | 2014-01-31 |
US20120045418A1 (en) | 2012-02-23 |
CN102256608A (en) | 2011-11-23 |
JP2012512842A (en) | 2012-06-07 |
AU2009336668A1 (en) | 2011-07-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ZA201104349B (en) | Pharmaceutical preparation comprising supernatant of blood mononuclear cell culture | |
HK1250313A1 (en) | Stable pharmaceutical composition and methods of using same | |
ZA201008392B (en) | Treatment of pluripotent cells | |
PT2257155T (en) | Cryopreservation of biological cells and tissues | |
IL215643A0 (en) | Stable high protein concentration formulations of human anti-tnf-alpha-antibodies | |
GB0622394D0 (en) | Differentiation of pluripotent cells | |
PL2643010T3 (en) | Biologically active complex and its preparation | |
EP2227540A4 (en) | De-differentiation of human cells | |
HUE056843T2 (en) | Infusion of drugs | |
HK1221748A1 (en) | Bifidobacterium having activity of reducing amount of intestinal putrefacted substance | |
IL219901A0 (en) | Pharmaceutical composiitons for the stimulation of stem cells | |
EP2606916A4 (en) | Biological implant | |
GB0911042D0 (en) | Treatment of tumorigenic cells in solid tumours | |
EP2185720A4 (en) | Biological encoding of large numbers of cells | |
GB0808413D0 (en) | Stabilisation of blood cell conjugates | |
EP2619571A4 (en) | Human b1 cells and uses thereof | |
HK1131039A1 (en) | Pharmaceutical use of sophoricoside | |
EP2636415A4 (en) | Cell adhesive material for biological tissue | |
HUP1000407A2 (en) | Ph dependent pulsatile and sustained release pharmaceutical composition | |
HK1157387A1 (en) | Use of hsa-producing cells | |
EP2171069A4 (en) | Delivery of nucleic acids into genomes of human stem cells using in vitro assembled mu transposition complexes | |
EP2651430A4 (en) | Biological activity of placental protein 13 | |
GB201019937D0 (en) | Biologically active complex and its preparation | |
AU2009904390A0 (en) | Provision of animal healthcare | |
GB0808280D0 (en) | Methods of preparing cell populations |